Bayer CropScience Ltd

As of 11-Nov, Bayer CropScience Ltd's stock price is Rs 4,506.85, down 2.83%, with a year-to-date return of -18.85%. The stock is underperforming its sector and the broader market, reflecting poor financial performance and negative growth indicators.

Bayer CropSci. has shown increasing net sales, reaching 5,473.40 Cr in March 2025, but experienced declines in operating profit, profit before tax, and profit after tax. Despite asset growth to 5,236.20 Cr, cash flow from operating activities significantly decreased, resulting in a net cash outflow of 271.00 Cr.

Bayer CropScience's latest Q2 FY26 results show strong revenue and profit growth, with net sales up 82.97% sequentially and net profit up 94.50%. However, declining operating margins and long-term profitability concerns suggest challenges ahead.

As of 06-Nov, Bayer CropScience Ltd's stock price is Rs 4,754.70, down 1.68% and has underperformed significantly with a year-to-date return of -14.39%. The stock is in a bearish trend, trading below moving averages, and has seen declining investor participation and poor long-term growth prospects.

As of October 17, 2025, Bayer CropScience is considered overvalued with a PE ratio of 38.24 and a year-to-date return of -9.24%, indicating it may not be a favorable investment compared to its peers and the Sensex.

As of October 17, 2025, Bayer CropSci. is considered overvalued with high valuation ratios and has underperformed against the Sensex, leading to a valuation grade change from very expensive to expensive.

As of October 17, 2025, Bayer CropScience is considered overvalued with a PE ratio of 38.24 and an expensive valuation grade, underperforming with a year-to-date return of -9.24% compared to the Sensex's 7.44%.

As of October 16, 2025, Bayer CropSci. exhibits a bearish trend with significant weakness, indicated by bearish MACD, moving averages, and KST across multiple time frames, despite a mildly bullish signal from Dow Theory.

As of October 16, 2025, Bayer CropSci. is considered very expensive and overvalued with a PE ratio of 38.93 and an EV to EBITDA of 30.61, underperforming with a year-to-date return of -7.58% compared to the Sensex's 6.82%.

Bayer CropSci has experienced consistent growth in net sales and total assets from Mar'19 to Mar'25, but profitability metrics have declined recently, with operating profit and net cash flow facing challenges.

As of 24-Sep, Bayer CropScience Ltd's stock price is 5,035.05, down 0.71%, and has declined 5.9% over the last three days. Despite strong financial results and high management efficiency, the stock is underperforming its sector and trading below key moving averages, indicating a bearish trend.

As of September 23, 2025, Bayer CropScience is considered overvalued with a PE ratio of 38.56 and an EV to EBITDA of 30.30, indicating a premium compared to peers, and its year-to-date return of -8.70% has underperformed against the Sensex's 5.07%.

As of 23-Sep, Bayer CropScience Ltd's stock price is Rs 5,070.90, down 3.17% and underperforming against the Sensex, which has risen 0.98% over the past month. The stock is trading below key moving averages and has seen a significant drop in investor participation, indicating a bearish trend.

Bayer CropSci. has experienced steady growth in net sales, reaching 5,473.40 Cr in March 2025, but faced declining profitability with operating profit dropping to 809.30 Cr and a significant decrease in cash flow, resulting in a net cash outflow of 271.00 Cr. Total assets and liabilities increased, driven by higher inventories.